NASDAQ · INM
InMed Pharmaceuticals Inc.
$1.63+$0.03 (+1.61%)
InMed Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 30.26% below the high.
Loading market information…
NASDAQ · GRI · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
GRI Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.55% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
GRI Bio, Inc.’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -$0.84. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow GRI Bio, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:10 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$162.40-53.24% vs estimate |
| $0.00 |
| Q3 2024 | Nov 14, 2024 | -$319.18+8.14% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.63+$0.03 (+1.61%)
InMed Pharmaceuticals Inc.’s quoted price sits in the upper half of its reported 52-week range, 30.26% below the high.
$4.77+$0.26 (+5.76%)
CNS Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.74% below the high.
$2.04-$0.06 (-2.86%)
Jaguar Health, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.81% below the high.
$0.95+$0.10 (+11.87%)
60 Degrees Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.01% below the high.
$1.69+$0.04 (+2.42%)
Can-Fite BioPharma Ltd.’s quoted price sits in the lower half of its reported 52-week range, 86.37% below the high.
$0.68-$0.02 (-3.39%)
Calidi Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.49% below the high.
$1.25-$0.09 (-6.72%)
Silo Pharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.02% below the high.
$0.52$0.00 (0.0%)
Abpro Corporation’s quoted price sits in the lower half of its reported 52-week range, 97.1% below the high.
